CNBC October 29, 2025
Key Points
– Eli Lilly and Walmart said they have teamed up to boost access to the pharma giant’s weight loss drug Zepbound, allowing U.S. patients to access vials of the blockbuster injection at direct-to-consumer prices through retail locations for the first time.
– Starting in mid-November, cash-paying patients with a prescription can purchase single-dose vials of Zepbound at discounts of 50% or more through the retailer’s nearly 4,600 pharmacy locations or via home delivery.
– Eli Lilly is working to maintain its dominance over rival Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
Eli Lilly and Walmart on Wednesday said they have teamed up to expand access to the drugmaker’s...
Today's Sponsors
Today's Sponsor